GLP-1 medications now contribute approximately 15% of monthly revenue at practices offering them, according to the data.
Марина Демешко at Adobe Stock
Recent data from Guidepoint Qsight reveals that GLP-1 medications for weight loss has reshaped the aesthetics market.Courtesy of Qsight Market ViewRecent data from Guidepoint Qsight reveals that GLP-1 medications for weight loss has reshaped the aesthetics market, with revenue at practices offering GLP-1 treatments increasing by an average of 9%, compared to a 2% decline at practices that did not offer these drugs.
Log in to view the full article
Recent data from Guidepoint Qsight reveals that GLP-1 medications for weight loss has reshaped the aesthetics market.Courtesy of Qsight Market ViewRecent data from Guidepoint Qsight reveals that GLP-1 medications for weight loss has reshaped the aesthetics market, with revenue at practices offering GLP-1 treatments increasing by an average of 9%, compared to a 2% decline at practices that did not offer these drugs.
Erik Haines, the managing director of Guidepoint Qsight says that, with insurance making it difficult to obtain coverage for GLP-1 medication, U.S. aesthetic practices have become a gateway for securing the medication outside of primary care providers.
GLP-1 use also introduces consumers into the world of medspa services. In fact, Guidepoint Qsight data found that about 40% of GLP-1 medspa patients in 2024 were completely new to those practices.
“By partnering with compounding pharmacies, these practices have been able to offer compounded forms of GLP-1 medications, which are not only more widely available than name-brand drugs like Ozempic and Wegovy, but also significantly cheaper,” Haines says.
Impact on Revenue
GLP-1 medications now contribute approximately 15% of monthly revenue at practices offering them, according to the data.
“Qsight data indicates that 2024 was a challenging year for many traditional aesthetics segments, including dermal fillers and energy-based devices,” Haines says. “Practices that incorporated GLP-1 medications into their offerings in 2024 saw robust growth, driven by the rapid and widespread adoption of these drugs in the U.S.”
Gen Z Begins to Age
While GLP-1 patients tend to skew older, with 62% of users being Gen X or older, Haines says 32% are millennials and 6% are Gen Z.
“As Gen Z continues to age into the aesthetics market, we expect this demographic to be a key driver of GLP-1 usage growth in the coming years,” Haines says.
Medspa vs. Aesthetic Physician Office Offerings
Medspas seem to offer GLP-1 treatments more widely, with 60% of medspas in the U.S. market now providing these services, compared to 35% of aesthetic physician offices.
Multiple factors contribute to higher GLP-1 drug adoption among medspas, Haines says. While aesthetic physician offices typically focus on surgical aesthetic procedures, medspas offer a wider range of non-surgical treatments such as weight loss supplements and drugs.
GLP-1 Services Challenge Some Surgical Procedures
“Certain surgical procedures focused on fat loss may be seen as direct competition to GLP-1 medications,” Haines says. “This potential overlap could make aesthetic physician office owners more hesitant to offer these drugs, for their potential impact on core surgical business.”
According to Guidepoint Qsight data, spending on surgical procedures remained relatively flat in 2024, reflecting the “ongoing shift toward non-surgical aesthetics.”
“GLP-1 medications have attracted a significant number of new customers to aesthetic practices,” Haines says. “However, these medications may also present challenges for certain segments, such as energy-based body contouring treatments—procedures [that] are typically expensive and focus on targeted body contouring, while GLP-1 drugs offer holistic weight loss at a cheaper price, which may better appeal to patients looking to get in shape.”